Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma

Who is this study for? Adults with Intrahepatic Cholangiocarcinoma
What treatments are being studied? Extend LymphAdenectomy
Status: Recruiting
Location: See all (13) locations...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Intrahepatic cholangiocarcinoma (ICC) is one of the common malignant tumors. Lymph node metastasis is an important factor affecting the poor prognosis of intrahepatic cholangiocarcinoma. The eighth edition of the AJCC guidelines recommends at least 6 lymph nodes to be used for staging. The American Hepatobiliary and Pancreatic Association also recommends the removal of hilar lymph nodes as part of the radical surgery for intrahepatic cholangiocarcinoma. However, some scholars have found that patients with regional lymph nodes have similar survival rates. This contradictory result has prompted more scholars to conduct clinical research to explore the necessity and standardization of lymph node dissection in intrahepatic cholangiocarcinoma.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

• Patients \>18 years of age and ≤80 years of age;

• Preoperative imaging and laboratory examination for intrahepatic cholangiocarcinoma, intraoperative frozen and postoperative pathology confirmed as intrahepatic cholangiocarcinoma; preoperative imaging assessment is resectable;

• No obvious lymph node metastasis in preoperative imaging; or negative intraoperative lymph node biopsy

• Liver function Child-Turcotte-Pugh score A-B grade;

• Residual liver volume \>30%; can tolerate radical hepatectomy

• The patient has autonomy, understands and voluntarily signs the written informed consent and is able to complete the follow-up plan;

• Sign the written informed consent form prior to the test screening.

Locations
United States
Maryland
The Johns Hopkins Hospital
RECRUITING
Baltimore
Other Locations
China
China-Japan Friendship Hospital
RECRUITING
Beijing
Chinese PLA General Hospital
RECRUITING
Beijing
Hunan Provincial People's Hospital
RECRUITING
Changsha
West China Hospital Sichuan University
RECRUITING
Chengdu
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
RECRUITING
Guangzhou
The Second Affiliated Hospital Zhejiang University School of Medicine
RECRUITING
Hanzhou
Zhejiang cancer hospital
RECRUITING
Hanzhou
The Affiliated Hospital of Inner Mongolia Medical University
RECRUITING
Hohhot
Renji Hospital Affiliated to Shanghai Jiao Tong University
RECRUITING
Shanghai
Xinhua Hospital Affiliated to Shanghai Jiao Tong University
RECRUITING
Shanghai
Zhong Shan Hospital Fudan University
RECRUITING
Shanghai
The First Affiliated Hospital of Xi 'an Jiaotong University
RECRUITING
Xi’an
Contact Information
Primary
Jiang-Tao LI, PHD;MD
zjulijiangtao@163.com
86-15906686716
Time Frame
Start Date: 2020-01-01
Estimated Completion Date: 2027-12-31
Participants
Target number of participants: 168
Treatments
Experimental: Extend LymphAdenectomy
Expanded lymph node dissection for right liver tumors included stations 12, 8, and 13, and stations 12, 1, 3, 7, and 8 for left liver tumors
No_intervention: Regional LymphAdenectomy
Regional lymph node dissection for intrahepatic cholangiocarcinoma included station 12.
Sponsors
Leads: Second Affiliated Hospital, School of Medicine, Zhejiang University

This content was sourced from clinicaltrials.gov

Similar Clinical Trials